Previous Close | 41.55 |
Open | 41.28 |
Bid | 40.09 x 110000 |
Ask | 40.44 x 110000 |
Day's Range | 39.83 - 41.58 |
52 Week Range | 34.00 - 44.69 |
Volume | |
Avg. Volume | 1,498 |
Market Cap | 8.954B |
Beta (5Y Monthly) | 0.42 |
PE Ratio (TTM) | 28.83 |
EPS (TTM) | 1.40 |
Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
Forward Dividend & Yield | 1.18 (2.91%) |
Ex-Dividend Date | Jan 30, 2024 |
1y Target Est | 47.60 |
Key Insights Qiagen's estimated fair value is US$43.31 based on 2 Stage Free Cash Flow to Equity Qiagen's US$45.02...
QIAGEN's (QGEN) solid potential in the NGS platform buoys optimism for investors.
QIAGEN's (QGEN) Clinical Insight Interpret is the first NGS interpretation platform approved by IVDR for use in cancer and hereditary applications.